Inventory |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | Inventory On August 6, 2026, the Company received FDA accelerated approval for TUDRIQEV indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with an anti-PD-1 antibody-based regimen, and commenced capitalization of inventory from this date. Prior to August 6, 2026, regulatory approval and subsequent commercialization of TUDRIQEV, including the possibility of future economic benefits from the sales of TUDRIQEV, were not considered probable and inventory-related costs were expensed as incurred to research and development expenses. The inventory recognized on the balance sheet as of September 30, 2026 does not include any pre-launch inventory. There were no capitalized inventory costs recorded as of March 31, 2026. Inventory, net consisted of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||